Compare INFU & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INFU | ACIU |
|---|---|---|
| Founded | 2005 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.0M | 221.9M |
| IPO Year | 2005 | 2015 |
| Metric | INFU | ACIU |
|---|---|---|
| Price | $12.27 | $2.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $15.00 | $10.00 |
| AVG Volume (30 Days) | 173.4K | ★ 210.5K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 181.82 | N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $143,436,000.00 | N/A |
| Revenue This Year | $3.20 | $706.75 |
| Revenue Next Year | $7.31 | $321.13 |
| P/E Ratio | $62.40 | ★ N/A |
| Revenue Growth | ★ 6.36 | N/A |
| 52 Week Low | $7.29 | $2.03 |
| 52 Week High | $12.97 | $4.00 |
| Indicator | INFU | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 63.90 | 55.97 |
| Support Level | $8.40 | $2.13 |
| Resistance Level | $12.97 | $2.66 |
| Average True Range (ATR) | 0.71 | 0.12 |
| MACD | 0.19 | 0.04 |
| Stochastic Oscillator | 79.32 | 62.50 |
InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. The company's services are provided under two-reportable segments: Patient Services and Device Solutions. Maximum revenue is generated from its Patient Services segment, which provides Durable Medical Equipment (DME) and treatment consumables, handles order and delivery logistics, provides 24/7 nursing support relating to the provided equipment, assumes responsibility for third-party payer Durable Medical Equipment billing, and handles biomedical services for the Durable Medical Equipment. The Device Solutions segment includes equipment rental and sales, consumable sales, and biomedical support services.
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.